Last reviewed · How we verify
NCT05979545: RAPID
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Phase 4 trial testing Rapid Diagnostics in Blood Stream Infections in 1,900 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | National University of Singapore |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,900 |
| Start date | 12 December 2023 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 4 locations across Taiwan, Malaysia, Thailand |
Drugs / interventions tested
- Rapid Diagnostics
Conditions studied
- Blood Stream Infections — all drugs for Blood Stream Infections →
- Ventilator Associated Pneumonia — all drugs for Ventilator Associated Pneumonia →
- Healthcare Associated Infection — all drugs for Healthcare Associated Infection →
- Carbapenem-Resistant Enterobacteriaceae Infection — all drugs for Carbapenem-Resistant Enterobacteriaceae Infection →
Sponsor
National University of Singapore
Who can join
Eligibility, any sex, with Blood Stream Infections or Ventilator Associated Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to propose a seamless intervention linking rapid bacterial isolate identification and antibiotic resistance gene detection and targeted antibiotic prescription to minimise time between infection onset and appropriate treatment in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales infections. This is an investigator initiated trial. The primary hypothesis is that these interventions will lead to improved clinical outcomes amongst patients with hospital-acquired bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to carbapenem non-susceptible Pseudomonas aeruginosa or Enterobacterales, compared to standard antibiotic susceptibility testing. Patients will be randomised to either a control or intervention arm. Patients randomised to the intervention arm will have relevant specimens analysed by rapid microbiological diagnostics and will have early availability of ceftazidime-avibactam if appropriate. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics will be available to these patients as per usual institutional practice.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing <i>Enterobacterales</i> infections: a systematic review and meta-analysis.
Foo AL, Young B, Ng OT, Vasoo S. · · 2026 · PMID 41510205 · DOI 10.1093/jacamr/dlaf238
Verify or expand the search:
- PubMed search for NCT05979545
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National University of Singapore trials
Trials by the same sponsor.
- NCT07519642 — Frailty Improvement Through Technology With Informal Caregiver Supported Exercise (FITWISE) for Pre-frail and Frail Comm · NA · not yet recruiting
- NCT07525492 — Die-logue Program for Community Dwelling Adults: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07375459 — Community-based Mobile-assisted Brief Intervention for Smoking Cessation · NA · recruiting
- NCT07444073 — Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock · not yet recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05979545 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University of Singapore
- Last refreshed: 6 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05979545.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing